The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Status:
Not yet recruiting
Trial end date:
2023-10-17
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well anlotinib hydrochloride works in treating patients with
metastatic pheochromocytoma or paraganglioma. Anlotinib hydrochloride may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow
to the tumor.